{
    "nct_id": "NCT06158854",
    "official_title": "An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis",
    "inclusion_criteria": "* Diagnosis of primary systemic immunoglobulin light chain (AL) amyloidosis.\n* Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.\n* Have at least 1 organ historically impacted by AL amyloidosis.\n* Considered AL amyloidosis risk stage 1, 2, or 3a and have measurable disease of AL amyloidosis as defined by difference between involved and uninvolved free light chains (dFLC) >= 50 mg/L.\n* Has previously been exposed to a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.\n* Known allergic reaction, significant sensitivity, or intolerance to constituents of the study drugs (and excipients) and/or other products in the same class.\n* Participant has the following conditions:\n\n  * Other non-AL amyloid disease;\n  * Previous or current diagnosis of symptomatic multiple myeloma (MM), including the presence of lytic bone disease, plasmacytomas, >= 60% plasma cells in the bone marrow, or hypercalcemia (defined as corrected calcium > 11 mg/dL);\n  * Active plasma cell leukemia (i.e., either 20% of peripheral white blood cells or > 2.0 × 109/L circulating plasma cells by standard differential);\n  * Waldenström's macroglobulinemia;\n  * Acute diffuse infiltrative pneumopathy;\n  * Major surgery within 28 days prior first dose or planned during study participation;\n  * History of organ transplant requiring continued use of immunosuppressants;\n  * Acute infections within 14 days prior first dose requiring parenteral therapy (antibiotic, antifungal, or antiviral);\n  * Participant has received an autologous stem cell transplant (SCT) within 12 weeks or an allogeneic SCT within 1 year of the first dose of study drug treatment.",
    "miscellaneous_criteria": ""
}